Searching in Pharma & Drug Safety · Search everything
2,366 changes Pharma & Drug Safety
Patent Application for Recyclable Polymer Material and Monomer
The USPTO has published a patent application (US20260085055A1) for a novel monomer and a chemically recyclable polymer material comprising the same. The application, filed by the Korea Institute of Science and Technology, describes a monomer formed by bonding a pentagonal cyclic olefin molecule with a photosensitive molecule to enable chemical recycling.
Patent Application US20260085058A1 for SOS1 Degraders Treating Cancers
The USPTO has published patent application US20260085058A1, which relates to compounds that degrade son of sevenless homolog 1 (SOS1) and their use in treating cancers, particularly KRAS-mutant cancers. The application was filed on August 11, 2023.
Patent Application for Nitrogen-Containing Heterocyclic Derivative Inhibitor
The USPTO has published a patent application (US20260085045A1) for a nitrogen-containing heterocyclic derivative inhibitor. The application details a compound, its preparation method, and its use in treating diseases such as cardiovascular and cerebrovascular conditions.
Patent Application: Dual Function Compounds for Cancer Treatment
The USPTO has published patent application US20260085046A1, filed on August 7, 2025, for dual function compounds intended for cancer treatment. The application discloses compounds of Formula (I) and their use in treating cancer.
Triphenylazole Compound Patent Application for Synucleinopathy Treatment
The USPTO has published a patent application (US20260085047A1) filed by Shiratori Pharmaceutical Co., Ltd. for a triphenylazole compound intended for the treatment or prevention of synucleinopathy. The application details the compound's structure and its potential use in pharmaceutical compositions.
ACSS2 Inhibitors for Cancer, Alcoholism, Viral Infections
The USPTO has published a patent application (US20260085048A1) detailing novel ACSS2 inhibitors and their potential uses in treating cancer, alcoholism, and viral infections. The application was filed on September 8, 2025.
Ergothioneine Crystal Form Patent Application
The USPTO has published a patent application (US20260085049A1) for a novel crystal form of ergothioneine and its preparation method. The application details a method for producing high-purity ergothioneine with low moisture content, intended for use in dietary supplements, foods, and cosmetics.
Triple Kinase Inhibitors for Cancer Treatment
The USPTO has published a patent application (US20260085050A1) for triple kinase inhibitor compounds designed for cancer treatment. The application details compounds that inhibit EGFR, ALK, and MET simultaneously, along with methods for treating cancer using these inhibitors.
WHO Accredited by Green Climate Fund for Climate and Health
The World Health Organization (WHO) has been accredited by the Green Climate Fund (GCF), enabling access to new funding for climate and health initiatives. This accreditation will support projects aimed at protecting communities from the health impacts of climate change, particularly in low- and middle-income countries.
WHO Report: 60+ Countries Include Refugees in Health Policies
The World Health Organization (WHO) released a report indicating that over 60 countries now include refugees and migrants in their national health policies. The report, based on data from 93 Member States, establishes a baseline for inclusive health systems but highlights remaining gaps in data collection, emergency preparedness, and culturally responsive care.
Dupilumab for Uncontrolled COPD with Raised Eosinophils
NICE has issued technology appraisal guidance TA1142 recommending dupilumab (Dupixent) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) and raised blood eosinophils. The guidance provides evidence-based recommendations for healthcare professionals.
Health Product InfoWatch: March 2026
Health Canada's March 2026 Health Product InfoWatch details recalls and safety updates for various medications, including Bicillin L-A, Bortezomib, Cefazolin, MAR-Amlodipine, and Seasonique/Seasonale. It also announces new market authorizations with conditions for Voxzogo and product monograph updates for Stivarga.
TGA Opens Consultation on Sunscreen Regulation Improvements
The Therapeutic Goods Administration (TGA) has opened an 8-week public consultation on proposed improvements to sunscreen regulation in Australia. The consultation seeks feedback on options to enhance SPF testing reliability, adopt new technologies, strengthen laboratory oversight, and improve labelling and quality assurance.
TGA Issues Infringement Notices for Unlawful Importation of Therapeutic Goods
The TGA has issued infringement notices totalling $23,760 to three health practitioners for allegedly importing unapproved therapeutic goods unlawfully. These goods, including unregistered botulinum toxin and hyaluronic acid, have not been assessed by the TGA and may pose health risks.
USPTO Patent Application: Cannabinoid Delivery Capsules
The USPTO has published a new patent application (US20260083756A1) from Fertin Pharma A/S for capsules designed for peroral cannabinoid delivery. The application details formulations using self-emulsifying drug delivery systems (SEDDS) with specific surfactant and cannabinoid content.
USPTO Patent Application for Tavapadon in Parkinson's Disease Treatment
The USPTO has published a patent application (US20260083740A1) detailing methods for treating Parkinson's Disease using escalating doses of tavapadon. The application was filed on September 23, 2025, by inventor Sridhar Duvvuri.
USPTO Patent Application for Photoprotective System
The USPTO has published a patent application (US20260083654A1) for a photoprotective system consisting of four specific sunscreens, assigned to PIERRE FABRE DERMO-COSMETIQUE. The application details a cosmetic or pharmaceutical composition with a photoprotective system representing 4% to 20% by weight.
USPTO Patent Application: Tooth Whitening Preparation System
The USPTO has published a patent application (US20260083653A1) for a tooth whitening preparation system and method filed by Cobea AG. The application describes a component system including an active ingredient component and an activation component designed to adjust the pH for a physiologically acceptable tooth whitening preparation.
USPTO Patent Application for Renewable Ester Emollient
The USPTO has published a patent application (US20260083652A1) for a renewable ester emollient for enhanced cutaneous permeation, assigned to Oxiteno S.A. Indústria e Comércio. The application details a personal care formulation and a method for moisturizing skin or hair using this emollient.
USPTO Patent Application for Skin Care Formulations
The USPTO has published a patent application (US20260083651A1) for skin care formulations. The application details a method of treating skin and a topical composition including various extracts and active ingredients. The filing date for this application was December 4, 2025.
USPTO Patent Application: Oral Care Compositions
The USPTO has published a new patent application from Colgate-Palmolive Company for oral care compositions containing amino acids and flavor components. The application details methods of making and using these stabilized compositions, aiming to combine traditionally incompatible ingredients.
USPTO Patent Application: Oral Care Composition with Mint Oil and Tin
The USPTO has published a new patent application (US20260083649A1) for an oral care composition. The invention involves a blend of mint oil, tin, and flavor extract designed to prevent the formation of methyl mercaptan, a compound that can cause unpleasant odors.
USPTO Patent Application: Deodorant Compositions
The USPTO has published a patent application (US20260083648A1) for deodorant compositions described by Dr. Squatch, LLC. The application details specific ingredient percentages for stick deodorants, emphasizing a high percentage of natural or naturally-derived ingredients.
USPTO Patent Application: Topical Delivery Systems
The USPTO has published a new patent application (US20260083647A1) detailing topical delivery systems and multi-phase formulations. The application describes sustained-release barrier formulations designed for skin application, potentially offering time-dependent effects like hair follicle softening and delayed active ingredient delivery.
USPTO Patent Application: Method for Forming Drops Dispersion
The USPTO has published a patent application detailing a method for forming a dispersion with fatty and aqueous phases, including specific steps for creating and conveying fatty phase drops. This application, filed by inventors Duncan Gilbert and Mathieu Goutayer, outlines a novel approach to dispersion formation for potential use in various product formulations.
USPTO Patent Application: RNA Complexes for Cancer Metastasis Treatment
The USPTO has published a new patent application detailing RNA complexes and nanostructures for cancer metastasis treatment. The application describes a one-step CMC production method for RNA therapeutic complexes containing nucleoside analogues, which self-assemble during RNA synthesis.
USPTO Patent Application: Inflammasome Inhibition for Neuroprotection
The USPTO has published a new patent application detailing methods for treating retinal detachment using inflammasome inhibition. The application, filed by Jayakrishna Ambati, Peirong Huang, and Kameshwari Ambati, focuses on improving visual outcomes for patients with rhegmatogenous retinal detachment.
USPTO Patent Application: Solid Dosage Form of Antiviral Nucleoside
The USPTO has published a new patent application from Merck Sharp & Dohme LLC for an oral dosage form of a small molecule antiviral nucleoside. The application details specific formulation components and pellet size requirements for the antiviral drug.
USPTO Patent Application: Neurodegenerative Disorder Treatment
The USPTO has published a new patent application (US20260083766A1) detailing methods for treating neurodegenerative disorders by modulating RNA editing. The application was filed on May 16, 2025, by inventors Nandkishore Raghav Belur and Joseph Robert Mazzulli.
USPTO Patent Application: Sialic Acid Compositions for Coronavirus Infections
The USPTO has published a patent application (US20260083762A1) detailing compositions comprising sialic acid for inhibiting or treating coronavirus infections, specifically those caused by SARS-CoV-2. The application was filed on August 18, 2025, by inventor Jan Remmereit.
USPTO Patent Application for NAD+ Concentration Support Compositions
The USPTO has published a patent application (US20260083765A1) for compositions and methods designed to support, optimize, and/or improve NAD+ concentrations in humans. The application details specific combinations of ingredients, including nicotinamide riboside, vitamins, and minerals.
USPTO Patent Application: Neuronal Migration Promoter for Brain Disease Treatment
The USPTO has published a patent application (US20260083761A1) from Public University Corporation Nagoya City University for a pharmaceutical composition and method to promote neuronal migration for treating brain diseases. The application details the use of a neuraminidase inhibitor.
USPTO Patent Application: Beta-1,3'-galactosyllactose for Gut Barrier Function Diseases
The USPTO has published a patent application (US20260083764A1) from N.V. Nutricia detailing the use of beta-1,3'-galactosyllactose for treating gut barrier function diseases, particularly in infants and young children. The application was filed on November 24, 2025.
USPTO Patent Application for Fiber-Based Prebiotic Dietary Supplements
The USPTO has published a patent application (US20260083763A1) for liquid compositions containing fiber as a prebiotic dietary supplement. The application details formulations designed to maintain or improve gut microbiome health.
USPTO Patent Application: Stable Liquid Bortezomib Formulations
The USPTO has published a patent application (US20260083760A1) for stable liquid bortezomib formulations filed by Riconpharma LLC. The application describes liquid compositions with specific impurity limits for intravenous or subcutaneous use.
USPTO Patent Application: Psychedelics Combined with NMDA Receptor Agonists
The USPTO has published a patent application (US20260083759A1) detailing combinations of psychedelic drugs with NMDA receptor agonists for treating neuropsychiatric and neurologic disorders. The application was filed on August 29, 2023, and is scheduled for publication on March 26, 2026.
USPTO Patent Application for Self-Emulsifying Drug Delivery Systems
The USPTO has published a patent application from Fertin Pharma A/S for a dosage form utilizing self-emulsifying drug delivery systems (SEDDS) for cannabinoids. The application details specific formulations including surfactants with PEG moieties and isolated or synthetic cannabinoids.
USPTO Patent Application for Tyk2 Inhibitor Dosage Forms
The USPTO has published a patent application (US20260083734A1) for novel dosage forms of Tyk2 inhibitors, specifically BMS-986165, intended for treating autoimmune and inflammatory diseases. The application details stable and bioavailable formulations, including spray-dried dispersions in a polymer matrix.
USPTO Patent Application: TYK2 Inhibitor Dosage Forms
The USPTO has published a patent application (US20260083733A1) for novel dosage forms of a TYK2 inhibitor, BMS-986165, intended for treating autoimmune diseases. The application details stable and bioavailable formulations, including spray-dried dispersions in a solid polymer matrix.
Testosterone Composition for Oral Delivery Treats Hypogonadism
The USPTO has published a patent application (US20260083755A1) assigned to NEUROCRINE UK LIMITED for a testosterone-containing pharmaceutical composition adapted for oral delivery. The application details treatment regimens and methods for hormone-related conditions like hypogonadism in human subjects.
USPTO Patent Application: Orally Disintegrating Corticosteroid Tablets for GI Inflammation
The USPTO has published a patent application (US20260083754A1) for orally disintegrating corticosteroid tablet compositions designed to treat gastrointestinal inflammation, specifically eosinophilic esophagitis. The application details the use of topically acting corticosteroids adsorbed onto a pharmaceutically acceptable carrier.
USPTO Patent Application: Upadacitinib Pharmaceutical Composition
The USPTO has published a new patent application (US20260083732A1) detailing a pharmaceutical composition for upadacitinib. The application, filed on September 6, 2023, describes a formulation involving upadacitinib, a hydrophobic release-controlling polymer, a pH modifier, and other excipients.
Uveal Melanoma Treatment Patent Application
The USPTO has published a patent application (US20260083731A1) detailing methods for treating uveal melanoma using a PKC inhibitor. The application, filed on August 25, 2023, by inventors Matthew Anthony Maurer, Michael Gabriel O'Quigley, and Julie Hambleton, focuses on neoadjuvant and/or adjuvant therapy to reduce metastasis and preserve eye function.
USPTO Patent Application for Metabolic Syndrome Treatment
The USPTO has published a patent application (US20260083753A1) for compositions and methods to treat metabolic syndrome. The application, filed by Kotha Sekharam, details improved compositions with enhanced solubility and bioavailability.
Patent Application: Cancer Treatment Methods and Compositions
The USPTO has published a patent application (US20260083752A1) for methods and compositions for treating cancer. The application, filed by the Regents of the University of Minnesota, involves the combination of p300/CBP modulators with senotherapeutics.
USPTO Patent Application: Allosteric Modulators for CRPC Therapy
The USPTO has published a patent application (US20260083751A1) from the University of Pittsburgh detailing allosteric modulators of the androgen receptor for treating castration-resistant prostate cancer (CRPC). The application describes small molecule compounds that may inhibit androgen receptor coactivator recruitment.
USPTO Patent Application: Dapiprazole for Eye Disorders
The USPTO has published a patent application (US20260083730A1) for a method of treating eye disorders using dapiprazole. The application, filed by Baradaina LLC, details a liquid composition for treating conditions such as presbyopia, glaucoma, or halos and glare.
USPTO Patent Application: Small Molecule Inhibitors of KRAS Proteins for Cancer Treatment
The USPTO has published a patent application (US20260083750A1) detailing small molecule inhibitors of KRAS proteins for cancer treatment. The application describes compounds that can inhibit specific KRAS protein mutants and their potential utility as therapeutic agents for cancer.
USPTO Patent for Anti-CD123 Immunoconjugates Treating AML
The USPTO has published a patent application (US20260083749A1) for anti-CD123 immunoconjugates, such as pivekimab sunirine, for treating acute myeloid leukemia (AML). The patent covers methods of use as monotherapies or in combination with other agents to achieve remission or prepare patients for transplant.
USPTO Patent Application: Compositions for Mitochondrial Health
The USPTO has published a patent application (US20260083747A1) detailing compositions for supporting mitochondrial health using methylthioninium salts combined with other compounds. The application was filed on October 30, 2024, by inventors Darren Lopez and Dan Schmidt.